Lincomycin
Lincomycin is an antibiotic used to treat certain serious bacterial infections caused by susceptible organisms, particularly Gram-positive bacteria and anaerobic bacteria. It belongs to the lincosamide class and works by binding to the 50S ribosomal subunit, inhibiting bacterial protein synthesis and preventing bacterial growth. It is available in injectable formulations and, in some markets, as oral capsules. Common side effects include nausea, vomiting, diarrhoea, abdominal discomfort, and skin rash. Important precautions include the risk of antibiotic-associated colitis, including severe Clostridioides difficile infection, and the need for caution in patients with a history of gastrointestinal disease or liver impairment. Lincomycin should be used only for appropriate bacterial infections under medical supervision, with careful monitoring for severe diarrhoea or allergic reactions.
Lincomycin was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Lincomycin, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Lincomycin from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Lincomycin, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
